VOSPIRE ER Rx
Generic Name and Formulations:
Albuterol (as sulfate) 4mg; ext-rel tabs.
DAVA Pharmaceuticals, Inc.
Indications for VOSPIRE ER:
Swallow whole. 4–8mg every 12 hours; max 32mg/day in 2 divided doses (every 12 hours).
Swallow whole. <6yrs: not recommended. ≥6yrs: 4mg every 12 hours; max 24mg/day in 2 divided doses.
Avoid excessive use. Sensitivity to sympathomimetics. Discontinue if paradoxical bronchospasm or cardiovascular effects occur. Cardiovascular disease (eg, coronary insufficiency, arrhythmias, hypertension). Diabetes. Hyperthyroidism. Seizure disorders. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Avoid MAOIs, tricyclics within 14 days (increased cardiovascular effects). Oral sympathomimetics: not recommended. Antagonized by β-blockers. Monitor digoxin. Caution with other drugs that lower serum potassium.
Tremor, headache, nervousness, GI upset, tachycardia, muscle cramps, insomnia, dizziness, somnolence, weakness, CNS stimulation, difficulty in micturition, hypokalemia, paradoxical bronchospasm, rash.
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness